[go: up one dir, main page]

WO2011109726A3 - Homologous multi-specific antibodies - Google Patents

Homologous multi-specific antibodies Download PDF

Info

Publication number
WO2011109726A3
WO2011109726A3 PCT/US2011/027222 US2011027222W WO2011109726A3 WO 2011109726 A3 WO2011109726 A3 WO 2011109726A3 US 2011027222 W US2011027222 W US 2011027222W WO 2011109726 A3 WO2011109726 A3 WO 2011109726A3
Authority
WO
WIPO (PCT)
Prior art keywords
specific antibodies
homologous
homologous multi
bind
relevant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/027222
Other languages
French (fr)
Other versions
WO2011109726A2 (en
WO2011109726A9 (en
Inventor
Jay M. Short
Hwai Wen Chang
Gerhard Frey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioatla Inc
Original Assignee
Bioatla Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Inc filed Critical Bioatla Inc
Publication of WO2011109726A2 publication Critical patent/WO2011109726A2/en
Publication of WO2011109726A3 publication Critical patent/WO2011109726A3/en
Publication of WO2011109726A9 publication Critical patent/WO2011109726A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention is relevant to the generation and optimization of homologous multi-specific antibodies, antibodies that are distinguished by their ability to bind to multiple antigens with high specificity and with high affinity. The invention is also relevant to other multi-specific proteins that bind more than one target.
PCT/US2011/027222 2010-03-05 2011-03-04 Homologous multi-specific antibodies Ceased WO2011109726A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33953310P 2010-03-05 2010-03-05
US61/339,533 2010-03-05

Publications (3)

Publication Number Publication Date
WO2011109726A2 WO2011109726A2 (en) 2011-09-09
WO2011109726A3 true WO2011109726A3 (en) 2012-01-26
WO2011109726A9 WO2011109726A9 (en) 2012-03-08

Family

ID=44542856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/027222 Ceased WO2011109726A2 (en) 2010-03-05 2011-03-04 Homologous multi-specific antibodies

Country Status (1)

Country Link
WO (1) WO2011109726A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2966088T3 (en) 2010-07-16 2024-04-18 Bioatla Inc New methods of protein evolution
US9969813B2 (en) * 2012-05-10 2018-05-15 Bioatla, Llc Multi-specific monoclonal antibodies
CN106459960A (en) 2014-05-13 2017-02-22 生物蛋白有限公司 Conditionally active biological proteins
RU2764074C2 (en) 2014-08-28 2022-01-13 Байоатла, Ллк Conditionally active chimeric antigen receptors for modified t-cells
TWI844509B (en) 2016-05-13 2024-06-11 美商拜奧亞特拉公司 Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN109475627B (en) * 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 Antibody mixtures
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN112513081A (en) 2018-06-14 2021-03-16 生物蛋白有限公司 Multispecific antibody constructs
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN113966397A (en) 2019-03-08 2022-01-21 黑曜石疗法公司 Human Carbonic Anhydrase 2 Compositions and Methods for Tunable Regulation
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US20070111260A1 (en) * 2005-10-14 2007-05-17 Medimmune, Inc. Cell display of antibody libraries
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
WO2011009058A2 (en) * 2009-07-17 2011-01-20 Bioatla, Llc Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US20070111260A1 (en) * 2005-10-14 2007-05-17 Medimmune, Inc. Cell display of antibody libraries
WO2011009058A2 (en) * 2009-07-17 2011-01-20 Bioatla, Llc Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts

Also Published As

Publication number Publication date
WO2011109726A2 (en) 2011-09-09
WO2011109726A9 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
WO2011109726A3 (en) Homologous multi-specific antibodies
HK1210620A1 (en) Multi-specific monoclonal antibodies
WO2013064701A3 (en) Specific antibodies and their isolation with anti-idiotypic antibodies
EA201391298A1 (en) NONWATER CONCENTRATED SUSPENSION COMPOSITIONS WITH REDUCED VISCOSITY BASED ON ANTIBODIES
MX340556B (en) Activatable bispecific antibodies.
WO2011056644A3 (en) Anti-glp-1r antibodies and their uses
WO2012125733A3 (en) Antibody screening methods
EA201390785A1 (en) ANTIBODIES THAT HAVE LOW AFFINITY TO HEMATOEPHALIC BARRIER RECEPTORS AND THEIR APPLICATIONS
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
HK1207654A1 (en) Modified antibody regions and uses thereof
WO2014150877A3 (en) Anti-tau antibodies and methods of use
WO2011097301A3 (en) METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
WO2013188693A8 (en) Antigen binding constructs to cd3
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
UA111818C2 (en) ANTIBODY AGAINST CSF-1R
EA201201016A1 (en) ANTI-AUDIO ANTICOAGULANTS
MX336682B (en) Antibodies against human csf-1r and uses thereof.
WO2014106015A3 (en) Multivalent binding protein compositions
WO2012131555A3 (en) Hetero-dimeric immunoglobulins
EA201291065A1 (en) ANTIBODIES AGAINST VLA-4
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
AR082518A1 (en) ANTIBODIES AGAINST IL-18R1 AND USES OF THE SAME
NZ600470A (en) Anti-c4.4a antibodies and uses thereof
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11751433

Country of ref document: EP

Kind code of ref document: A2